You just read:

Mirati Therapeutics' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative For NSCLC Patients

News provided by

Mirati Therapeutics, Inc.

Oct 12, 2017, 16:45 ET